Ph+ acute lymphoblastic leukemia
Conditions
Interventions
Group 1:Flumatinib maintenance treatment
Group 2:Dasatinib maintenance therapy
Sponsors
University of Electronic Science and Technology Affiliated Hospital·Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Ph+ acute lymphoblastic leukemia patients receiving allogeneic hematopoietic stem cell transplantation in our department from June 2021 to June 2023; 2. Aged 14 to 60 years, no gender limit; 3. ECOG score 0-3 points; 4. The patient must be able to understand and be willing to participate in this study, and sign an informed consent form at the same time.
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant, preparing to become pregnant or breast-feeding; 2. Patients secondary to myelodysplastic syndrome (MDS), chronic myeloproliferative disease (MPN) and lymphatic system proliferative disease; 3. Patients with severe liver, kidney and other important organ dysfunctions or diseases that affect the prognosis of treatment; 4. Combine other diseases that cannot be controlled and may restrict patients from participating in this trial. 5. The investigator believes that it is not suitable to join, and any situation that the investigator believes may increase the risk of the subject or interfere with the test results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival;Residual disease;Cumulative recurrence rate;Proportion of interrupted treatment due to adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival rate;Recurrence-free survival of graft-versus-host disease; | — |
Countries
China
Contacts
Public ContactYang Xi
University of Electronic Science and Technology Affiliated Hospital·Sichuan Provincial People's Hospital
Outcome results
None listed